To the Editor
In a previous communication (1), we traced the history of spending on cardiovascular disease (CVD) treatment, prevention, and research since 1996. As we noted there, such spending estimates naturally lead to the question of whether the money has been well spent. To begin to address this question, we extend our previous results to provide a preliminary indication of the cost-effectiveness of these expenditures and to identify gaps in the cost-effectiveness literature.